Recombinant Mouse Lipocalin-13 Protein, CF

Recombinant Mouse Lipocalin-13 Protein, CF Summary

Product Specifications

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: Lipocalin-13

Recombinant Mouse Lipocalin-13, also known as Odorant-Binding Protein 2a, is a member of the Lipocalin family of small secreted proteins, which are involved in a variety of biological processes including chemical communication, cell proliferation and differentiation, metabolism, reproduction, immune responses, and cancer development (1). Members of this family share a highly-conserved tertiary structure with a characteristic beta -barrel at the center (1). This central cavity binds to small lipophilic molecules, including fatty acids, retinol, steroids, odorants, and pheromones, allowing Lipocalins to regulate the transportation, stability, release, and activity of these molecules (1). Mouse Lipocalin-13 is synthesized as a 176 amino acid (aa) precursor that contains a 19 aa signal sequence and a 157 aa mature region. It has been suggested that the Lipocalin-13 precursor undergoes proteolytic processing because two isoforms with molecular weights between 20 and 29 kDa have been identified on SDS-PAGE (2). Mature mouse Lipocalin-13 shares 69% and 36% aa sequence identity with the rat and human orthologs, respectively.</p><p /><p>Lipocalin-13 is expressed and secreted by multiple tissues in mice including liver, pancreas, and skeletal muscle (2). It has been shown to regulate glucose and lipid metabolism (2, 3). Lipocalin-13 deficiency is associated with obesity and is thought to contribute to hyperglycemia, insulin resistance, glucose intolerance and hepatic steatosis in obese mice (2, 3). Additionally, Lipocalin-13 has been shown to have anti-diabetogenic effects. It suppresses hepatic glucose production, uptake of circulating glucose by adipocytes, and induction of fatty acid oxidation by liver, possibly by stimulating CPT-1 alpha production (1-3)

Related Research Areas

• Diabetes
• Obesity